{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:44:47Z","timestamp":1783547087852,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0760-4","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T12:04:10Z","timestamp":1571400250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pericardial effusion under nivolumab: case-reports and review of the literature"],"prefix":"10.1136","volume":"7","author":[{"given":"Anastasia","family":"Saade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mansuet-Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mirabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"issue":"18","key":"760_CR1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378.","journal-title":"N Engl J Med"},{"key":"760_CR2","first-page":"139","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 1990. 2016;54:139\u201348.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"760_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"760_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"key":"760_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.","journal-title":"J Immunother Cancer."},{"issue":"18","key":"760_CR6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"key":"760_CR7","doi-asserted-by":"crossref","unstructured":"Thibault C, Vano Y, Soulat G, Mirabel M. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J. 2018;10.","DOI":"10.1093\/eurheartj\/ehy485"},{"key":"760_CR8","first-page":"794842","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842.","journal-title":"Case Rep Oncol Med"},{"issue":"3","key":"760_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1078155216635853","volume":"23","author":"CA Dasanu","year":"2017","unstructured":"Dasanu CA, Jen T, Skulski R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2017;23(3):231\u20134.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"17","key":"760_CR10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"760_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","volume":"123","author":"N Palaskas","year":"2019","unstructured":"Palaskas N, Morgan J, Daigle T, Banchs J, Durand J-B, Hong D, et al. Targeted Cancer therapies with pericardial effusions requiring Pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol. 2019;123(8):1351\u20137.","journal-title":"Am J Cardiol"},{"issue":"6","key":"760_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/imt-2019-0003","volume":"11","author":"M Asai","year":"2019","unstructured":"Asai M, Kato Y, Kawai S, Watanabe K, Yomota M, Okuma Y, et al. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. Immunotherapy. 2019;11(6):467\u201372.","journal-title":"Immunotherapy."},{"issue":"6","key":"760_CR13","first-page":"1102","volume":"14","author":"M Altan","year":"2019","unstructured":"Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, et al. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(6):1102\u20138.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"760_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2019.00004","volume":"9","author":"M Yamasaki","year":"2019","unstructured":"Yamasaki M, Daido W, Saito N, Funaishi K, Okada T, Kawamoto K, et al. Pericardial effusion with Tamponade in lung Cancer patients during treatment with Nivolumab: a report of two cases. Front Oncol. 2019;9:4.","journal-title":"Front Oncol"},{"key":"760_CR15","doi-asserted-by":"crossref","unstructured":"Shaheen S, Mirshahidi H, Nagaraj G, Hsueh C-T. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol [Internet]. 2018 May 8;7. Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5941729\/","DOI":"10.1186\/s40164-018-0104-y"},{"key":"760_CR16","doi-asserted-by":"crossref","unstructured":"Vittorio A, Sharma R, Siejka D, Bhattarai K, Hardikar A. Recurrent pericardial effusion while receiving Nivolumab for metastatic lung adenocarcinoma: case report and review of the literature. Clin Lung Cancer. 2018;26.","DOI":"10.1016\/j.cllc.2018.05.010"},{"key":"760_CR17","first-page":"101","volume":"22","author":"P Zarogoulidis","year":"2017","unstructured":"Zarogoulidis P, Chinelis P, Athanasiadou A, Tsiouda T, Trakada G, Kallianos A, et al. Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. Respir Med Case Rep. 2017;22:101\u20135.","journal-title":"Respir Med Case Rep"},{"key":"760_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","volume":"4","author":"BC Kolla","year":"2016","unstructured":"Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer. 2016;4:80.","journal-title":"J Immunother Cancer"},{"key":"760_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","volume":"222","author":"J Nesfeder","year":"2016","unstructured":"Nesfeder J, Elsensohn AN, Thind M, Lennon J, Domsky S. Pericardial effusion with tamponade physiology induced by nivolumab. Int J Cardiol. 2016;222:613\u20134.","journal-title":"Int J Cardiol"},{"key":"760_CR20","doi-asserted-by":"crossref","unstructured":"de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy. J Immunother [Internet]. 2018 Feb 16 [cited 2018 Apr 12];Publish Ahead of Print. Available from: \nhttps:\/\/insights-ovid-com.hellebore.biusante.parisdescartes.fr\/pubmed?pmid=29461982","DOI":"10.1097\/CJI.0000000000000217"},{"issue":"1","key":"760_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000447053","volume":"136","author":"I Kushnir","year":"2016","unstructured":"Kushnir I, Wolf I. Nivolumab-induced pericardial Tamponade: a case report and discussion. Cardiology. 2016;136(1):49\u201351.","journal-title":"Cardiology."},{"issue":"31","key":"760_CR22","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(31):3541\u20133.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"760_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/eji.200636435","volume":"37","author":"J Wang","year":"2007","unstructured":"Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129\u201338.","journal-title":"Eur J Immunol"},{"issue":"16","key":"760_CR24","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"760_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11886-017-0866-6","volume":"19","author":"B Xu","year":"2017","unstructured":"Xu B, Harb SC, Cremer PC. New insights into pericarditis: mechanisms of injury and therapeutic targets. Curr Cardiol Rep. 2017;19(7):60.","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"760_CR26","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560\u201375.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"760_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer."}],"updated-by":[{"DOI":"10.1186\/s40425-019-0822-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0760-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:25Z","timestamp":1601055925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0760-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0760-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40425-019-0822-7","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors reported that authors\u2019 given and family names haven been incorrectly tagged.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective non-interventional case series does not enter the Jard\u00e9 law. Consequently, this study did not require the approval of the French Ethical Research Committee, according to the French legislation. Patients were informed at hospital admission that medical data from medical records may potentially be used anonymously for data collections of health-related data for research purposes, with respect to the law on the protection of personal data. Consent to participate was based on a non-opposition procedure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was based on a non-opposition statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}